Loading market dashboard
Sona Nanotech Inc.
SNANFHealthcareOTCCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
4:20pm: Easing tensions Markets finished the session on a strong note, with major US indexes extending their winning streak as geopolitical tensions showed...
The gas keeping the world's MRI scanners running and AI chips cool is suddenly in critically short supply. Six ASX-listed companies could find themselves in...
12:55pm: Sliding oil propels stocks "Crude futures prices fell sharply - dropping over 10% to below $86 per barrel and reaching near five-week lows - after...
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review...
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory board to support its ongoing clinical and research initiatives. Dr.
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the appointment of two oncologists, Michael Smylie and Jonathan Trites, to its scientific advisory...
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) said tissue analysis from its first human trial of its heat-based cancer therapy showed immune system activation in late-stage melanoma patients, raising hopes it could be combined with existing immunotherapy drugs to improve their effectiveness. The Canadian biotech firm said analysis conducted at Dalhousie University found natural killer cell infiltration in tumor tissue after treatment with its Targeted Hyperthermia Therapy (THT), a marker associated with innate immune response.
Shares in Alien Metals (AIM: UFO) rose 16% to 0.12p after the company reported progress at two separate joint venture projects in the Pilbara region of...
FTSE down 82 points at 10,354 Oil and gas prices remain elevated Pres Trump set a 1am GMT deadline for Iran deal 4.03pm: Defence and aerospace stocks...
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the publication of a preclinical study examining the efficacy of its Targeted Hyperthermia Therapy (THT) in combination with immunotherapy for cancer treatment. The study, published in the Journal of Nanobiotechnology, evaluated the therapy in an immunologically “cold” colorectal cancer (CT26) model.
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) has announced the publication of a preclinical study examining the efficacy of its Targeted Hyperthermia Therapy...
